Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523918 | 0.92 | EDNRA (0.41) | EDNRAAGTR1EDNRB | |
| SCHEMBL30171054 | 0.92 | EDNRA (0.41) | EDNRAAGTR1EDNRB | |
| SCHEMBL535104 | 0.90 | EDNRA (0.43) | EDNRAAGTR1EDNRB | |
| SCHEMBL30757240 | 0.90 | EDNRA (0.43) | EDNRAAGTR1EDNRB | |
| SCHEMBL28571209 | 0.88 | EDNRA (0.36) | EDNRAAGTR1 | |
| SCHEMBL5530883 | 0.88 | EDNRA (0.42) | EDNRAAGTR1EDNRB | |
| SCHEMBL15728330 | 0.88 | EDNRA (0.38) | EDNRAAGTR1EDNRB | |
| SCHEMBL5523038 | 0.85 | EDNRA (0.39) | EDNRAAGTR1EDNRB | |
| SCHEMBL5531210 | 0.84 | EDNRA (0.41) | EDNRAAGTR1EDNRB | |
| SCHEMBL30171097 | 0.84 | EDNRA (0.41) | EDNRAAGTR1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662312-B2 | Method for treating glomerulosclerosis | LIGAND PHARMACEUTICALS INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-06-18 | — | — | US | disclosed |
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | LIGAND PHARMACEUTICALS INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | EDNRA 3/4885AGTR1 4/4885EDNRB 2/4885 |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | EDNRA 3/4885AGTR1 4/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.